Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,654,799

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat

Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.

Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 0.81% and 0.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?

Smart Beta ETF report for EDOW

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.

Exploring Analyst Estimates for Amgen (AMGN) Q2 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.

Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?

On Affimed's (AFMD) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline candidates being developed for various cancer indications.

Amgen (AMGN) Advances But Underperforms Market: Key Facts

In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.

Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?

Ginkgo's (DNA) total revenues are likely to have declined in the second quarter, owing to the expected ramp-down of the company's K-12 COVID testing services.

Amgen (AMGN) Stock Moves -0.39%: What You Should Know

Amgen (AMGN) closed at $334.30 in the latest trading session, marking a -0.39% move from the prior day.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.